athira pharma stock buy or sell

NASDAQATHA stock a buy or a sell. This rating change essentially reflects an upward trend in.

Athira Pharma Announces Pricing Of Initial Public Offering

How to buy shares in Athira Pharma Inc.

. The average Athira Pharma stock price prediction forecasts a potential upside of 43872 from the current ATHA share price of 297. View all in Stocks. The average rating score is and is based on 7 buy ratings 2 hold ratings and 0 sell ratings.

Common Stock ATHA Stock Quotes - Nasdaq offers stock quotes market activity data for US and global markets. Perceptive Advisors LLC is the largest individual. What is ATHAs Earnings Per Share EPS forecast for.

If youre looking for a quick scoop on ATHA stock chart price target market cap news and buy or sell analysis go to Finny and look for ATHA. ATHA appears an attractive pick as it has been recently upgraded to a Zacks Rank 2 Buy. Compare share trading platforms.

Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients. Youll get all this info in one place. Athira Pharma Inc.

Use our comparison table to help you find a platform that fits you. Get the latest Athira Pharma Inc. Athira Pharma ATHA stock is plummeting on Wednesday following the outcome of a Phase 2.

Its product pipeline includes ATH-1017 ATH-101920 and ATH. Insiders have sold a total of 14767 Athira Pharma shares in the last 24 months for a total of 3972323 sold. Is Athira Pharma Inc.

Buy or Sell this stock. ATHA is owned by 5841 institutional shareholders 2945 Athira Pharma insiders and 1214 retail investors. ATHA stock price news buy or sell recommendation and investing advice from Wall Street professionals.

What was the 52-week low for. Athira Pharma Inc stock is lower by -3343 since Friday September 18 2020 when the stock began trading and the average rating from Wall Street analysts is a Strong. How much insider selling is happening at Athira Pharma.

Open your brokerage account. Athira Pharma stock has received a consensus rating of buy. Check out the forecast and prediction here.

See what the analysts say. Engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Get Wall Street analysts ratings for Athira Pharma Inc.

Is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop.

Athira Pharma Crunchbase Company Profile Funding